chelation
Showing 26 - 50 of 252
Beta Thalassemia Major Anemia, Iron Overload Trial in Cairo, Jakarta (Deferiprone oral solution, Placebo)
Completed
- Beta Thalassemia Major Anemia
- Iron Overload
- Deferiprone oral solution
- Placebo
-
Cairo, Egypt
- +3 more
Feb 9, 2021
Sexual Maturation in ß-Thalassemia Major Assiut University
Unknown status
- β-Thalassemia Major Patients Receiving Chelation Therapy
- FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males
- (no location specified)
Feb 19, 2019
Myelodysplastic Syndrome, Iron Overload Trial in Canada, United States (Deferasirox)
Completed
- Myelodysplastic Syndrome
- Iron Overload
-
Birmingham, Alabama
- +47 more
Jul 21, 2021
Bone Denisty Change in Children With Beta Thalassemia Major
Not yet recruiting
- Evaluate Bone Denisty Changes in Children With Beta Thalassemia Major
- Dexa scan
- (no location specified)
Sep 29, 2023
SAH, Dementia Trial in Iowa City (Deferiprone pill, , Montreal Cognitive Assessment)
Recruiting
- SAH
- Dementia
- Deferiprone pill
- +2 more
-
Iowa City, IowaUnivesity of Iowa Hospital and Clinics
Mar 7, 2022
MDS Trial in France (transplantation)
Active, not recruiting
- MDS
- transplantation
-
Amiens, France
- +36 more
Jul 4, 2022
Transfusion-dependent Beta-thalassemia After Gene Therapy
Recruiting
- Transfusion-dependent Beta-Thalassemia
- Gene Therapy
- Gene therapy
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Aug 6, 2023
Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia Trial in Worldwide (Deferasirox dispersable tablet
Completed
- Transfusion-dependent Thalassemia
- Non-transfusion-dependent Thalassemia
- Deferasirox dispersable tablet (DT)
- Deferasirox film coated tablet (FCT)
-
Alexandria, Egypt
- +16 more
Sep 6, 2021
Thalassemia, Beta Trial in Karachi (Hydroxyurea and Thalidomide)
Completed
- Thalassemia, Beta
- Hydroxyurea and Thalidomide
-
Karachi, Sindh, PakistanChildren's Hospital Karachi
Nov 23, 2023
Immunological Pure Red Cell Aplasia Trial (Isatuximab)
Not yet recruiting
- Immunological Pure Red Cell Aplasia
- (no location specified)
Sep 26, 2022
Erythroid Response in Myelodysplasia Undergoing Chelation
Unknown status
- Myelodysplasia
- +2 more
-
Alessandria, AL, Italy
- +19 more
Jul 29, 2019
Wilson Disease Trial in Germany, United Kingdom, United States
Recruiting
- Wilson Disease
-
New Haven, Connecticut
- +5 more
Jul 27, 2022
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Cladribine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2022
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
MDS Trial in Worldwide (Deferasirox, Placebo)
Different Risk Factors on Growth Parameters of Thalassemic
Not yet recruiting
- Thalassemia Major
- serum ferritin and AST
- (no location specified)
Mar 29, 2022
Thalassemia in Children Trial in Alexandria (Benson's Relaxation technique, Music therapy)
Active, not recruiting
- Thalassemia in Children
- Benson's Relaxation technique
- Music therapy
-
Alexandria, Egyptthe Hematology Out-Patient Clinic of the Children's University H
Feb 13, 2023
Insulin Secretion Trial in Vellore (Ferrous sulphate)
Completed
- Insulin Secretion
- Ferrous sulphate
-
Vellore, Tamil Nadu, IndiaChristian Medical College
Feb 11, 2022
Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major Trial in Nashville (EDIT-301)
Recruiting
- Transfusion Dependent Beta Thalassemia
- +3 more
- EDIT-301
-
Oakland, California
- +3 more
Jan 3, 2023
Chronic Iron Overload Trial in Worldwide (Deferiprone, Deferasirox)
Completed
- Chronic Iron Overload
-
Lushnjë, Albania
- +21 more
Apr 8, 2021
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Recruiting
- Sickle Cell Disease
- +3 more
- GWAS
-
Boston, Massachusetts
- +24 more
Apr 4, 2023